Systemic infusion of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis in mice

Digestive Diseases and Sciences

Volumn 57, Issue 12, 2012, Pages 3136-3144

  He, Xiao Wen ^a   He, Xiao Sheng ^a   Lian, Lei ^a   Wu, Xiao Jian ^a   Lan, Ping ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Colitis; Inflammatory bowel diseases; Mesenchymal stem cells; Mice; Treatment

Indexed keywords

INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOODY DIARRHEA; CELL CULTURE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DESCENDING COLON; DISEASE SEVERITY; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECTUM HEMORRHAGE; ULCERATIVE COLITIS; WEIGHT REDUCTION;

ANIMALS; BONE MARROW CELLS; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; GENE EXPRESSION REGULATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICE, INBRED BALB C; RNA, MESSENGER; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 84871638604     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2290-5     Document Type: Article

References (33)

1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627-1640.
2. Xavier RJ, Podilsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
3. Kucharzik T, Maaser C, Lügering A, et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis. 2006;12:1068-1083.
4. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol. 2003;171:3426-3434.
5. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31:890-896.
6. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008;2:313-319.
7. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 2007;213:341-347.
8. Jones E, McGonagle D. Human bone marrow mesenchymal stem cells in vivo. Rheumatology (Oxford). 2008;47:126-131.
9. Brooke G, Cook M, Blair C, et al. Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol. 2007;18:846-858.
10. Pǎunescu V, Deak E, Herman D, et al. In vitro differentiation of human mesenchymal stem cells to epithelial lineage. J Cell Mol Med. 2007;11:502-508.
11. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726-736.
12. Fibbe WE, Nauta AJ, Roelofs H. Modulation of immune responses by mesenchymal stem cells. Ann N Y Acad Sci. 2007;1106:272-278.
13. Noël D, Djouad F, Bouffi C, et al. Multipotent mesenchymal stromal cells and immune tolerance. Leuk Lymphoma. 2007;48:1283-1289.
14. Zhang B, Liu R, Shi D, et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood. 2009;113:46-57.
15. Rinden O, Uzunel M, Rassmuson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390-1397.
16. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439-1441.
17. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus host disease: a phase II study. Lancet. 2008;371:1579-1586.
18. Wirtz S, Neufert C, Weigmann B. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2:541-546.
19. Naito Y, Takagi T, Kuroda M, et al. An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium induced colitis in mice. Inflamm Res. 2004;53:462-468.
20. Obermeier F, Kojouharoff G, Hans W, et al. Interferon-gamma (IFN-gamma) and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol. 1999;116:238-245.
21. Ogata H, Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Des. 2003;9:1107-1113.
22. Gonzalez MA, Gonzalez-Rey E, Rico L, et al. Treatment of experimental arthritis by inducing immune tolerance with human adipose derived mesenchymal stem cells. Arthr Rheum. 2009;60:1006-1019.
23. Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther. 2009;17:939-946.
24. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stemcells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005;106:1755-1761.
25. Prevosto C, Zancolli M, Canevali P, et al. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007;92:881-888.
26. Kong QF, Sun B, Bai SS, et al. Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-beta. J Neuroimmunol. 2009;207:83-91.
27. Phinney D, Prockop D. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdiffererentiation and modes of tissue repair - current views. Stem Cells. 2007;25:2896-2902.
28. Abdallah BM, Kassem M. Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther. 2008;15:109-116.
29. Komori M, Tsuji S, Tsujii M, et al. Involvement of bone marrow-derived cells in healing of experimental colitis in rats. Wound Repair Regen. 2005;13:109-118.
30. Brittan M, Chance V, Elia G, et al. A regenerative role for bone marrow following experimental colitis: contribution to neovasculogenesis and myofibroblasts. Gastroenterology. 2005;128:1984-1995.
31. Khalil PN, Weiler V, Nelson PJ, et al. Nonmyeloablative stem cell therapy enhances microcirculation and tissue regeneration in murine inflammatory bowel disease. Gastroenterology. 2007;132:944-954.
32. Bernardo ME, Zaffaroni N, Novara F, et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007;67:9142-9149.
33. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003;102:3837-3844.